MISSISSAUGA, ON, Nov. 11, 2011 /CNW/ - YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today reported operational and financial results for its first quarter of fiscal 2012, ended September 30, 2011.
132114
YM BioSciences reports operational and financial results for the first quarter of fiscal 2012
35205
Flextronics to report first quarter results
149158
Denbury Resources announces first quarter results
67539
YM BioSciences reports nimotuzumab approved for marketing in Mexico
3472
ACCO Brands Corporation reports first quarter 2009 results
95101
IParty Corp. reports financial results for first quarter 2012
172203
BioIQ raises $2.5M
46740
BioLineRx announces publication of pre-clinical results
145070
The Gymboree Corporation to review first fiscal quarter 2011 financial results
165685
Biocrossroads seed fund makes first investments
25334
Biotage announces global launch of Syro Wave microwave and parallel peptide synthesizer
63842
SM Prime posts 12 percent profit growth in first quarter
77990
Daiichi Sankyo to support and co-sponsor phase 1 clinical study
113210
Biogen Idec to report fourth quarter and year end 2010 financial results on February 1, 2011
49370
CGGVeritas announces first quarter 2011 results
39059
Nbk reports a net profit of $264m for the first quarter of 2010
130150
FDA approves first cord blood product